Drug intelligence / Profile preview

LINK-004

Development stage: Preclinical
Lead developer: LinkGevity
Modality: Small Molecules

Overview

LINK-004 is a preclinical-stage necrosis inhibitor being developed by LinkGevity, a UK-based AI-driven drug discovery company. It is a component of the company's Anti-Necrotics™ platform, which utilizes the proprietary 'Blueprint Theory of Aging' to identify and target biological pathways involved in uncontrolled cell death (necrosis). LINK-004 is reported to block necrosis by approximately 90% and is currently in the lead optimization phase for an undisclosed therapeutic indication. The Anti-Necrotics™ platform is being developed for a range of applications, including kidney disease, organ preservation, and tissue engineering. LinkGevity has received support from Innovate UK, the Francis Crick Institute, and was selected for NASA's SPACE-H accelerator program.

Beyond the preview

Go deeper on LINK-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LINK-004.

Explore the full profile